natgillin/translations-raw huggingface dataset:
Patients in the Vitamin D3 2,800 group received FOSAVANCE (70 mg/2,800 IU) (n=299) and patients in the Vitamin D3 5,600 group received FOSAVANCE (70 mg/2,800 IU) plus an additional 2,800 IU vitamin D3 (n=309) once a week; additional vitamin D supplements were allowed. 
Bolnice v skupini "Vitamin D3 2.800" so prejemale zdravilo FOSAVANCE (70 mg/2.800 i.e.) (n = 299), bolnice v skupini "Vitamin D3 5.600" pa so prejemale zdravilo FOSAVANCE (70 mg/2.800 i.e.) in dodatnih 2.800 i.e. vitamina D3 (n = 309) enkrat tedensko; dovoljeni so bili tudi drugi dodatki vitamina D. Po 24 tednih zdravljenja so bile povprečne vrednosti 25-hidroksivitamina D v serumu v skupini "Vitamin D3 5.600" pomembno višje (69 nmol/l [27,6 ng/ml]) kot v skupini "Vitamin D3 2.800" (64 nmol/l [25,5 ng/ml]).
FOSAVANCE 70 mg/5,600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘270' on the other. 
FOSAVANCE 70 mg/5.600 i.e. tablete imajo obliko modificiranega pravokotnika, so bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘270'.
FOSAVANCE 70 mg/2,800 IU tablets Aluminium/aluminium blisters, in cartons containing 2, 4, 6 or 12 tablets. 
FOSAVANCE 70 mg/2.800 i.e. tablete Pretisni omoti (aluminij/aluminij) v škatlah, ki vsebujejo 2, 4, 6 ali 12 tablet.
FOSAVANCE 70 mg/5,600 IU tablets Aluminium/aluminium blisters, in cartons containing 2, 4 or 12 tablets. 
FOSAVANCE 70 mg/5.600 i.e. tablete Pretisni omoti (aluminij/aluminij) v škatlah, ki vsebujejo 2, 4 ali 12 tablet.
What FOSAVANCE contains 
Kaj vsebuje zdravilo FOSAVANCE
Each FOSAVANCE 70 mg/2,800 IU tablet contains 70 mg alendronic acid (as sodium trihydrate) and 70 micrograms (2,800 IU) colecalciferol (vitamin D3). 
Ena FOSAVANCE 70 mg/2.800 i.e. tableta vsebuje 70 mg alendronske kisline (v obliki natrijevega trihidrata) in 70 mikrogramov (2.800 i.e.) holekalciferola (vitamina D3).
Each FOSAVANCE 70 mg/5,600 IU tablet contains 70 mg alendronic acid (as sodium trihydrate) and 140 micrograms (5,600 IU) colecalciferol (vitamin D3). 
Ena FOSAVANCE 70 mg/5.600 i.e. tableta vsebuje 70 mg alendronske kisline (v obliki natrijevega trihidrata) in 140 mikrogramov (5.600 i.e.) holekalciferola (vitamina D3).
BLISTER FOR FOSAVANCE 70 mg/2,800 IU 
ŠKATLA ZA ZDRAVILO FOSAVANCE 70 mg/2.800 i.e.
Every week, take one FOSAVANCE tablet on your chosen day. 
1) Izberite dan v tednu, ki vam najbolj ustreza, nato pa vsak teden na izbrani dan vzemite eno tableto FOSAVANCE.
How to take FOSAVANCE 
Kako jemati zdravilo FOSAVANCE
In patients with these conditions, serum calcium and symptoms of hypocalcaemia should be monitored during therapy with FOSAVANCE. 
Količina vitamina D v zdravilu FOSAVANCE ne zadošča za odpravo pomanjkanja vitamina D. Pri bolnikih s temi boleznimi je treba med zdravljenjem z zdravilom FOSAVANCE spremljati vrednost kalcija v serumu in simptome hipokalciemije.
EU/1/05/310/004 - 12 tablets 
EU/1/05/310/007 - 4 tablete EU/1/05/310/008 - 12 tablet
These side effects may worsen if patients continue to take FOSAVANCE after developing these symptoms. 
Če potem, ko so se že pojavili neželeni učinki, bolnik nadaljuje z jemanjem zdravila FOSAVANCE, se lahko neželeni učinki še poslabšajo.
FOSAVANCE 70 mg/2,800 IU tablets alendronic acid/colecalciferol 
FOSAVANCE 70 mg/2.800 i.e. tablete alendronska kislina/holekalciferol
Very common (may affect more than 1 in 10 people): 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov):
BLISTER FOR FOSAVANCE 70 mg/5,600 IU 
ŠKATLA ZA ZDRAVILO FOSAVANCE 70 mg/5.600 i.e.
FOSAVANCE 70 mg/5,600 IU tablets alendronic acid/colecalciferol 
FOSAVANCE 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
Each tablet contains 70 mg alendronic acid (as sodium trihydrate) and 70 micrograms (2,800 IU) colecalciferol (vitamin D3). 
Ena tableta vsebuje 70 mg alendronske kisline (v obliki natrijevega trihidrata) in 70 mikrogramov (2.800 i.e.) holekalciferola (vitamin D3).
There is important additional information about how to take FOSAVANCE in the package leaflet. 
V priloženem navodilu za uporabo so pomembne dodatne informacije o jemanju zdravila FOSAVANCE.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR FOSAVANCE 70 mg/2,800 IU 
PRETISNI OMOT ZA ZDRAVILO FOSAVANCE 70 mg/2.800 i.e.
How to store FOSAVANCE 
Shranjevanje zdravila FOSAVANCE
FOSAVANCE 70 mg/5,600 IU tablets alendronic acid /colecalciferol 
70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
Route of Administration 
Jakost
This summary was last updated on 09/01/2007. 
Ta povzetek je bil nazadnje posodobljen 09/01/2007.
Cortavance is given once a day for 7 days. 
Zdravilo Cortavance se daje enkrat dnevno 7 dni.
If no improvement is seen after 7 days, the treatment should be re-evaluated by a veterinarian. 
Če po 7 dneh ni izboljšanja, mora veterinar ponovno oceniti zdravljenje.
Do not smoke when applying this product. 
Pri ravnanju z zdravilom ne kadite.
Fifty-four dogs were treated with Cortavance and 51 with this other product. 
Štiriinpetdeset psov je bilo zdravljenih z zdravilom Cortavance, 51 pa s tem drugim zdravilom.
The treatment area should not normally exceed an area corresponding to the two flanks of the animal. 
Obseg zdravljene površine običajno ne sme presegati površine, ki ustreza obema bočnima stranema živali.
Information on the prescription status of this product may be found on the label/outer package. 
Informacije o predpisovanju tega izdelka najdete na nalepki/zunanji ovojnini.
Other information about Cortavance: 
Druge informacije o zdravilu Cortavance:
It is sprayed on the affected area, avoiding the eyes. 
Razprši se po prizadetem območju, vendar ne sme priti v stik z očmi.
The studies to determine the dose generally supported the chosen dose and the length of treatment. 
Raziskave za določanje odmerka so v splošnem potrdile izbrani odmerek in dolžino zdravljenja.
In case of accidental contact (skin, eye), wash thoroughly with water. 
V primeru nenamernega stika (koža, oko) mesto stika temeljito umijte z vodo.
The medicine should not normally be used in dogs suffering from Cushing's syndrome (a disorder where the body produces too much natural steroid), and in young animals (under 7 months of age) as steroids are known to slow growth. 
Zdravilo se običajno ne uporablja pri psih s Cushingovim sindromom (motnja, pri kateri telo proizvede preveč naravnega steroida) in pri mladih živalih (ki še nimajo 7 mesecev), saj je znano, da steroidi upočasnjujejo rast.
The pump delivers in two sprays enough medicine to treat an area of about 100 cm2. 
Z dvema sprožitvama črpalke dovedemo dovolj zdravila za zdravljenje površine velikosti približno 100 cm2.
Significant improvement of the skin condition was demonstrated in several studies under controlled conditions, whereas significant reduction of itching was demonstrated in only one of these laboratory studies in which the dogs received treatment against external parasites at the same time. 
Bistveno izboljšanje stanja kože je bilo dokazano v več raziskavah pri kontroliranih pogojih, medtem ko je bilo bistveno zmanjšanje srbenja dokazano le v eni takšni laboratorijski raziskavi, v kateri so psi hkrati prejemali zdravilo proti zunanjim zajedavcem.
The European Commission granted a marketing authorisation valid throughout the European Union, for Cortavance to Virback S.A. on 09/01/2007. 
Evropska komisija je dovoljenje za promet z zdravilom Cortavance, veljavno po vsej Evropski uniji, odobrila družbi Virbac S.A. dne 9. januarja 2007.
Before treatment, any other existing skin conditions (such as an infection) must be treated and Cortavance should not be used on skin ulcers. 
Pred zdravljenjem je treba ozdraviti vsa druga obstoječa stanja kože (na primer okužbe), zdravilo Cortavance pa se ne sme uporabljati pri kožnih razjedah.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) CORTAVANCE EPAR summary for the public 
EMEA/V/C/110 EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) CORTAVANCE Povzetek EPAR za javnost
The steroid is in a special chemical form (a diester) that makes it effective at low doses in skin conditions as the medicine is able to get into and remain longer in the outer layer of the skin. 
Steroid je posebna kemijska oblika (diester), ki zagotavlja učinkovitost pri nizkih odmerkih, saj se zdravilo lahko vpije v zunanji sloj kože in ostane v njem dalj časa.
In case of accidental ingestion, seek medical advice immediately and show the leaflet or the label to the physician. 
V primeru nenamernega zaužitja nemudoma poiščite medicinsko pomoč in pokažite zdravniku Navodila za uporabo ali nalepko.
Results from the field trial indicated comparable efficacy between Cortavance and the comparator product. 
Rezultati terenskega preizkušanja so pokazali primerljivo učinkovitost zdravila Cortavance in primerjalnega zdravila.
The spray is flammable and should not be used next to a naked flame or any incandescent material. 
Pršilo je vnetljivo, zato ga ne uporabljajte poleg odprtega ognja ali žarečih snovi.
The active substance in Cortavance, hydrocortisone aceponate, is a steroid which is a type of substance that helps to reduce inflammation. 
Zdravilna učinkovina zdravila Cortavance, hidrokortizon aceponat, je steroid, tj. vrsta snovi, ki pomaga zmanjšati vnetje.
What is the risk associated with Cortavance? 
Kakšna tveganja so povezana z zdravilom Cortavance?
The field trial consisted of a multi-site study comparing treatment of dogs with itchy skin conditions with Cortavance to treatment with a different steroid-containing product. 
Terenska raziskava je obsegala primerjalno multicentrično študijo, pri kateri so primerjali zdravljenje psov s srbečo kožo z zdravilom Cortavance z zdravljenjem z drugim zdravilom, vsebujočim steroid.
The clinical part of the dossier consisted of studies to determine the dose and of one field trial. 
Klinični del dokumentacije je obsegal raziskave, katerih namen je bil določitev odmerka, in eno preizkušanje na terenu.
What benefit has Cortavance shown during the studies? 
Kakšne koristi je zdravilo Cortavance izkazalo med raziskavami?
Spray preferably in a well ventilated area. 
Pršilo po možnosti uporabljajte v dobro prezračenem prostoru.
Cortavance is used to treat inflamed and itchy skin conditions in dogs. 
Zdravilo Cortavance se uporablja za zdravljenje vnetnih in srbečih stanj kože pri psih.
There are no side effects reported in animals who have been treated with Cortavance. 
Pri živalih, ki so bile zdravljene z zdravilom Cortavance, niso poročali o neželenih stranskih učinkih.
Why has Cortavance been approved? 
Zakaj je bilo zdravilo Cortavance odobreno?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Cortavance exceed the risks for the treatment of inflamed and itchy skin conditions and recommended that Cortavance be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je sklenil, da so koristi zdravila Cortavance pri zdravljenju vnetnih in srbečih stanj kože večje od z njimi povezanih tveganj.
Cortavance is a spray containing a solution of the active substance hydrocortisone aceponate. 
Zdravilo Cortavance je pršilo, ki vsebuje raztopino zdravilne učinkovine hidrokortizon aceponat.
What is Cortavance used for? 
Za kaj se zdravilo Cortavance uporablja?
How has Cortavance been studied? 
Kako je bilo zdravilo Cortavance raziskano?
What is Cortavance? 
Kaj je zdravilo Cortavance?
How does Cortavance work? 
Kako zdravilo Cortavance deluje?
Very rare, not known* 
Zelo redki, neznana pogostnost*
• Your doctor may order blood tests. 
• lahko vaš zdravnik naroči krvne preiskave.
Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to < 1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). 
Njihova pogostnost je navedena po naslednjem dogovoru: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Since the CAPRIE trial was not powered to evaluate efficacy of individual subgroups, it is not clear whether the differences in relative risk reduction across qualifying conditions are real, or a result of chance. 
Ker študija CAPRIE nima moči za oceno učinkovitosti v posameznih podskupinah, ni jasno, ali so razlike pri zmanjšanju relativnega tveganja glede na vključitvene pogoje resnične ali naključne.
Prevention of atherothrombotic events 
Preprečevanje aterotrombotičnih dogodkov
Some other medicines may influence the use of Clopidogrel dura or vice versa. 
Nekatera druga zdravila lahko vplivajo na jemanje zdravila Klopidogrel dura in obratno.
In the long-term safety follow-up of this study, 26 patients with the shunt still in place at one year of age received clopidogrel up to 18 months of age. 
Med dolgoročnim varnostnim spremljanjem te študije je 26 bolnikov, ki so pri enem letu starosti še vedno imeli spoj, prejemalo klopidogrel do 18.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake EXP.
• if you have had an allergy or reaction to any medicine used to treat your disease. 
• če ste imeli alergijo ali alergijsko reakcijo na katero koli zdravilo, ki ste ga jemali.
You should take Clopidogrel dura for as long as your doctor continues to prescribe it. 
Zdravilo Klopidogrel dura morate jemati, dokler vam ga vaš zdravnik predpisuje.
Clopidogrel is indicated in: 
Klopidogrel je indiciran pri:
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
• Preobčutljivost za zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
What Clopidogrel Dura is and what it is used for 
Kaj je zdravilo Klopidogrel Dura in za kaj ga uporabljamo
• Adults patients suffering from myocardial infarction (from a few days until less than 35 days), 
• Odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V .
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. 
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli zdravilo, tudi če ste ga dobili brez recepta.
You have been prescribed Clopidogrel dura to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral 
Klopidogrel dura vam je predpisan za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate otrdele arterije (znano tudi kot ateroskleroza) in - ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska
What Clopidogrel dura is and what it is used for What you need to know before you take Clopidogrel dura 
Kaj je zdravilo Klopidogrel dura in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzel zdravilo Klopidogrel dura
If you experience prolonged bleeding when taking Clopidogrel dura If you cut or injure yourself, it may take longer than usual for bleeding to stop. 
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel dura Če se urežete ali poškodujete, lahko traja dlje kot običajno, da se krvavitev ustavi.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
<Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/
The elimination half life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration. 
Razpolovni čas izločanja glavnega (neaktivnega) krožečega metabolita je bil 8 ur po enkratnem in večkratnem dajanju.
What you need to know before you take Clopidogrel Dura 
Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Dura
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups 
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve majhen in podoben v obeh skupinah.
There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies. 
Opravljene pa so bile številne retrospektivne analize za oceno tega učinka pri bolnikih, zdravljenih s klopidogrelom, za katere so na voljo rezultati genotipizacije: CURE (n = 2721), CHARISMA (n = 2428), CLARITY-TIMI 28 (n = 227), TRITON-TIMI 38 (n = 1477) poleg tega pa tudi številne objavljene kohortne študije.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure. 
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot preveidnostni ukrep zaželeno, da se klopidogrela v nosečnosti ne uporablja.
Date of latest renewal: 
Datum zadnjega podaljšanja dovoljenja za promet:
• Risk Management Plan (RMP) 
• Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO
• if you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain; 
• če imate zdravstveno stanje, ki trenutno povzroča krvavitev, npr. rana na želodcu ali možganska krvavitev;
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. 
Po peroralnem odmerku s 14C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
Do not take a double dose to make up for a forgotten tablet. 
Ne jemljite dvojnega odmerka, da bi nadomestili posamezne izpuščene odmerke.
Other medicines and Clopidogrel Dura 
Druga zdravila in zdravilo Klopidogrel Dura
Apart from the specific medicinal product interaction information described above, interaction studies with clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed. 
Razen zgoraj navedenih podatkov o specifičnih interakcijah z zdravili, študij klopidogrela z nekaterimi drugimi zdravili, ki jih bolniki z aterotrombotično boleznijo pogosto uporabljajo niso izvedli.
What Clopidogrel dura looks like and contents of the pack The film-coated tablets are pink, round and slightly convex. 
Izgled zdravila Klopidogrel dura in vsebina pakiranja Filmsko obložente tablete so rožnate, okrogle in rahlo izbočene.
The usual dose is one 75 mg tablet of Clopidogrel dura per day to be taken orally with or without food, and at the same time each day. 
Običajni odmerek je ena 75 mg tableta zdravila Klopidogrel dura na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction. 
Trombolitiki: Varnost sočasnega jemanja klopidogrela, fibrinsko specifičnih ali fibrinsko nespecifičnih trombolitikov in heparinov je bila ovrednotena pri bolnikih z akutnim miokardnim infarktom.
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery . 
V študiji CURE število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v sedmih dneh po koronarni premostitveni operaciji pri bolnikih, ki so zdravljenje prekinili več kot pet dni pred kirurškim posegom.
If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel dura: 
Če katerokoli od spodaj navedenih stanj velja za vas, morate o tem obvestiti svojega zdravnika, preden boste vzeli zdravilo Klopidogrel dura:
NAME OF THE MARKETING AUTHORISATION HOLDER Mylan dura GmbH 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Mylan dura GmbH
• if you suffer from severe liver disease; 
• če imate hudo jetrno obolenje;
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin, ATC code: B01AC04. 
Farmakoterapevtska skupina: antitrombotična zdravila, zaviralci agregacije trombocitov brez heparina, oznaka ATC: B01AC04.
Clopidogrel should not be used in children because of efficacy concerns (see section 5.1). 
• Pediatrična populacija Klopidogrel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte poglavje 5.1).
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects'). 
• morate takoj povedati zdravniku, če razvijete bolezensko stanje (znano tudi kot trombotična trombocitopenična purpura ali TTP) z zvišano telesno temperaturo in modricami pod kožo, ki se lahko pojavijo kot drobne rdeče pike, z ali brez nerazložljive hude utrujenosti, zmedenosti, porumenele kože ali oči (zlatenica) (glejte poglavje 4 »Možni neželeni učinki«).
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel dura. 
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden vzamete Klopidogrel dura.
If you become pregnant while taking Clopidogrel dura, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
Če med zdravljenjem z zdravilom Klopidogrel dura zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
Magyarország Mylan Kft Tel: 36 1 8026993 
Mylan Kft Tel: 36 1 8026993
In CURE, CLARITY and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status. 
V študijah CURE, CLARITY in eni od kohortnih študij (Trenk) niso odkrili večjega deleža dogodkov glede na metabolizatorsko stanje.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel dura. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Klopidogrel dura.
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%. 
V študiji CAPRIE je bila pri bolnikih, ki so se zdravili s klopidogrelom ali z ASA, skupna incidenca vseh krvavitev 9,3 %.
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =4.0%; CI: -22.5 to 11.7 [p=0.639]). 
Pri bolnikih, ki so bili v preizkušanje vključeni samo na podlagi nedavnega MI, je bil klopidogrel numerično inferioren, vendar se statistično ni razlikoval od ASA (zmanjšanje RT: -4 %; IZ: -22,5 do 11,7 /p = 0,639/).